-+ 0.00%
-+ 0.00%
-+ 0.00%

APTOSE’S TUSPETINIB TRIPLE DRUG THERAPY FEATURED AT THE 2025 ASH ANNUAL MEETING; HIGH RATE OF FRONTLINE CLINICAL RESPONSES CONTINUES ACROSS AML POPULATIONS

路透·12/06/2025 13:00:02

登录查看新闻详情